News aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Market Closed - Deutsche Boerse AG Other stock markets 02:13:15 2024-04-23 am EDT			5-day change	1st Jan Change
1.5 ^EUR	+2.04%		-2.60%	+16.28%

Mar. 15	RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	MT
Mar. 14	Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ATyr Pharma to Participate in April Investor Conferences	Apr. 01	AQ
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	Mar. 15	MT
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Atyr Pharma: Q4 Earnings Snapshot	Mar. 14	AQ
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	Mar. 14	AQ
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	Feb. 28	AQ
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	Feb. 21	AQ
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	Feb. 21	CI
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	Jan. 29	AQ
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	Jan. 18	AQ
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	Nov. 13	AQ
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Atyr Pharma: Q3 Earnings Snapshot	Nov. 09	AQ
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update	Nov. 09	AQ
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000	Nov. 09	MT
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD	Nov. 01	AQ
ATyr Pharma to Present at November Investor Conferences	Nov. 01	AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD	23-10-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Summary

Filters